{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:37:01Z","timestamp":1791599821719,"version":"4.3.4"},"reference-count":42,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sandoz Novartis","award":["R053"],"award-info":[{"award-number":["R053"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Inflammatory bowel diseases are chronic inflammation of the intestinal mucosa characterized by relapsing\u2013remitting cycle periods of variable duration. Infliximab (IFX) was the first monoclonal antibody used for the treatment of Crohn\u2019s disease and ulcerative colitis (UC). High variability between treated patients and loss of IFX efficiency over time support the further development of drug therapy. An innovative approach has been suggested based on the presence of orexin receptor (OX1R) in the inflamed human epithelium of UC patients. In that context, the aim of this study was to compare, in a mouse model of chemically induced colitis, the efficacy of IFX compared to the hypothalamic peptide orexin-A (OxA). C57BL\/6 mice received 3.5% dextran sodium sulfate (DSS) in drinking water for 5 days. Since the inflammatory flare was maximal at day 7, IFX or OxA was administered based on a curative perspective at that time for 4 days using intraperitoneal injection. Treatment with OxA promoted mucosal healing and decreased colonic myeloperoxidase activity, circulating concentrations of lipopolysaccharide-binding protein, IL-6 and tumor necrosis factor alpha (TNF\u03b1) and decreased expression of genes encoding cytokines in colonic tissues with better efficacy than IFX allowing for more rapid re-epithelization. This study demonstrates the comparable anti-inflammatory properties of OxA and IFX and shows that OxA is efficient in promoting mucosal healing, suggesting that OxA treatment is a promising new biotherapy.<\/jats:p>","DOI":"10.3390\/ijms24119554","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T03:06:00Z","timestamp":1685588760000},"page":"9554","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficiency of Orexin-A for Inflammatory Flare and Mucosal Healing in Experimental Colitis: Comparison with the Anti-TNF Alpha Infliximab"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0897-7612","authenticated-orcid":false,"given":"Anne","family":"Blais","sequence":"first","affiliation":[{"name":"UMR-PNCA, Universit\u00e9 Paris-Saclay, AgroParisTech, INRAE, 91120 Palaiseau, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna\u00efg","family":"Lan","sequence":"additional","affiliation":[{"name":"UMR-PNCA, Universit\u00e9 Paris-Saclay, AgroParisTech, INRAE, 91120 Palaiseau, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8501-0990","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Blachier","sequence":"additional","affiliation":[{"name":"UMR-PNCA, Universit\u00e9 Paris-Saclay, AgroParisTech, INRAE, 91120 Palaiseau, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Benamouzig","sequence":"additional","affiliation":[{"name":"UMR-PNCA, Universit\u00e9 Paris-Saclay, AgroParisTech, INRAE, 91120 Palaiseau, France"},{"name":"H\u00f4pital Avicenne, Assistance Publique-H\u00f4pitaux de Paris, 93000 Bobigny, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Jouet","sequence":"additional","affiliation":[{"name":"H\u00f4pital Avicenne, Assistance Publique-H\u00f4pitaux de Paris, 93000 Bobigny, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2912-5168","authenticated-orcid":false,"given":"Alain","family":"Couvineau","sequence":"additional","affiliation":[{"name":"INSERM UMR 1149\/Centre de Recherche sur l\u2019Inflammation (CRI), Facult\u00e9 de M\u00e9decine X. Bichat, Universit\u00e9 Paris Cit\u00e9, 75018 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"D\u00e9maris, A., Widigson, E.S.K., Ilvemark, J.F.K.F., Steenholdt, C., Seidelin, J.B., Huisinga, W., Michelet, R., Aulin, L.B.S., and Kloft, C. (2022). Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14102095"},{"key":"ref_2","first-page":"903","article-title":"Artificial intelligence-assisted endoscopy changes the definition of mucosal healing in ulcerative colitis","volume":"33","author":"Nakase","year":"2021","journal-title":"Dig. Endosc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5009\/gnl18203","article-title":"Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease","volume":"14","author":"Nakase","year":"2020","journal-title":"Gut Liver"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/nrgastro.2016.116","article-title":"Acute severe ulcerative colitis: From pathophysiology to clinical management","volume":"13","author":"Hindryckx","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2174\/1381612825666190405141410","article-title":"JAK Inhibition: The Most Promising Agents in the IBD Pipeline?","volume":"25","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s40262-017-0627-0","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease","volume":"57","author":"Hemperly","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3389\/fendo.2018.00573","article-title":"The Anti-tumoral Properties of Orexin\/Hypocretin Hypothalamic Neuropeptides: An Unexpected Therapeutic Role","volume":"27","author":"Couvineau","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/joim.13406","article-title":"Hypocretins (orexins): The ultimate translational neuropeptides","volume":"291","author":"Jacobson","year":"2022","journal-title":"J. Intern. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000514962","article-title":"Cellular Signaling Mechanisms of Hypocretin\/Orexin","volume":"45","author":"Kukkonen","year":"2021","journal-title":"Front. Neurol. Neurosci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3389\/fendo.2019.00709","article-title":"Orexins as Novel Therapeutic Targets in Inflammatory and Neurodegenerative Diseases","volume":"22","author":"Couvineau","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1016\/j.bbadis.2018.08.023","article-title":"Ectopic expression of OX1R in ulcerative colitis mediates anti-inflammatory effect of orexin-A","volume":"1864","author":"Messal","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1158\/0008-5472.CAN-10-3473","article-title":"Aberrant expression of OX1 receptors for orexins in colon cancers and liver metastases: An openable gate to apoptosis","volume":"71","author":"Voisin","year":"2011","journal-title":"Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12974-019-1447-y","article-title":"Systemic administration of orexin A ameliorates established experimental autoimmune encephalomyelitis by diminishing neuroinflammation","volume":"16","author":"Becquet","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e21055","DOI":"10.7554\/eLife.21055","article-title":"Peripherally administered orexin improves survival of mice with endotoxin shock","volume":"30","author":"Ogawa","year":"2016","journal-title":"eLife"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.3748\/wjg.v25.i27.3572","article-title":"Mucosal healing progression after acute colitis in mice","volume":"25","author":"Andriamihaja","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.3748\/wjg.v23.i33.6016","article-title":"Dextran sodium sulfate colitis murine model: An indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis","volume":"23","author":"Eichele","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Katsandegwaza, B., Horsnell, W., and Katherine Smith, K. (2022). Inflammatory Bowel Disease: A Review of Pre-Clinical Murine Models of Human Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23169344"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"100851","DOI":"10.1016\/j.disamonth.2019.02.004","article-title":"A comprehensive review and update on ulcerative colitis","volume":"65","author":"Gajendran","year":"2019","journal-title":"Dis. Mon."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/0161-5890(93)90106-L","article-title":"Construction and initial characterization of a mouse-human chimeric anti-TNF antibody","volume":"30","author":"Knight","year":"1993","journal-title":"Mol. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0140-6736(93)91375-V","article-title":"Tumour-necrosis-factor antibody treatment in Crohn\u2019s disease","volume":"342","author":"Derkx","year":"1993","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.cgh.2018.06.031","article-title":"Effect of Accelerated Infliximab Induction on Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-analysis","volume":"17","author":"Nalagatla","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3389\/fmed.2020.00517","article-title":"Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?","volume":"7","author":"Atreya","year":"2020","journal-title":"Front. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/apt.12644","article-title":"Systematic review with network meta-analysis: The efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis","volume":"39","author":"Stidham","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0196-9781(00)00369-7","article-title":"Immunoreactive orexin-A in human plasma","volume":"22","author":"Arihara","year":"2001","journal-title":"Peptides"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000079643","article-title":"Clinical significance of daytime plasma orexin-A-like immunoreactivity concentrations in patients with obstructive sleep apnea hypopnea syndrome","volume":"71","author":"Sakurai","year":"2004","journal-title":"Respiration"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1111\/bph.13287","article-title":"Crucial role of the orexin-B C-terminus in the induction of OX1 receptor-mediated apoptosis: Analysis by alanine scanning, molecular modelling and site-directed mutagenesis","volume":"172","author":"Nicole","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.neulet.2011.11.028","article-title":"Orexins promote survival of rat cortical neurons","volume":"506","author":"Zawilska","year":"2012","journal-title":"Neurosci. Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/ecco-jcc\/jjw053","article-title":"Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease","volume":"10","author":"Levin","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.crohns.2013.01.001","article-title":"Infliximab induces a dysregulated tissue-homing profile on human T-lymphocytes in-vitro: A novel mechanism for paradoxical inflammation?","volume":"7","author":"Peake","year":"2013","journal-title":"J. Crohns Colitis"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-alpha: Structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/gut.50.2.206","article-title":"Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn\u2019s disease","volume":"50","author":"Peppelenbosch","year":"2002","journal-title":"Gut"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/ibd.20000","article-title":"Synergistic effect of methotrexate and infliximab on activated lymphocyte apoptosis","volume":"13","author":"Peppelenbosch","year":"2007","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ibd.21818","article-title":"Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro","volume":"18","author":"Vos","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/cei.12872","article-title":"Anti-inflammatory effects of infliximab in mice are independent of tumour necrosis factor \u03b1 neutralization","volume":"187","author":"Assas","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","article-title":"TNF biology, pathogenic mechanisms and emerging therapeutic strategies","volume":"12","author":"Kalliolias","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"101927","DOI":"10.1016\/j.arr.2023.101927","article-title":"Nanomedical approaches in the realm of rheumatoid arthritis","volume":"87","author":"Radu","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"931970","DOI":"10.3389\/fendo.2022.931970","article-title":"The Orexin receptors: Structural and anti-tumoral properties","volume":"13","author":"Couvineau","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.1111\/bph.12883","article-title":"Calcium affects OX1 orexin (hypocretin) receptor responses by modifying both orexin binding and the signal transduction machinery","volume":"171","author":"Putula","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.chom.2021.06.019","article-title":"Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease","volume":"29","author":"Lee","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Pavel, F.M., Vesa, C.M., Gheorghe, G., Diaconu, C.C., Stoicescu, M., Munteanu, M.A., Babes, E.E., Tit, D.M., Toma, M.M., and Bungau, S. (2021). Highlighting the Relevance of Gut Microbiota Manipulation in Inflammatory Bowel Disease. Diagnostics, 11.","DOI":"10.3390\/diagnostics11061090"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Blais, A., Drouin, G., Chaumontet, C., Voisin, T., Couvelard, A., Even, P.C., and Couvineau, A. (2017). Impact of Orexin-A Treatment on Food Intake, Energy Metabolism and Body Weight in Mice. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0169908"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jnutbio.2014.09.007","article-title":"High-protein diet differently modifies intestinal goblet cell characteristics and mucosal cytokine expression in ileum and colon","volume":"6","author":"Lan","year":"2015","journal-title":"J. Nutr. Biochem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/11\/9554\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:46:06Z","timestamp":1760125566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/11\/9554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":42,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["ijms24119554"],"URL":"https:\/\/doi.org\/10.3390\/ijms24119554","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,31]]}}}